Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease.
about
The generation and function of soluble apoE receptors in the CNSApolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's diseaseApolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progressionNeighborhood psychosocial environment, apolipoprotein E genotype, and cognitive function in older adultsIntroduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein Ep21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesisApoE4 induces Aβ42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice.Apolipoprotein E: a major piece in the Alzheimer's disease puzzle.Applied neurogenomics.Age-dependent effect of apolipoprotein E4 on functional outcome after controlled cortical impact in miceNeuroplasticity in Alzheimer's disease.Interactions between the apolipoprotein E ε4 allele status and adverse childhood experiences on depressive symptoms in older adultsRegional-specific effects of ovarian hormone loss on synaptic plasticity in adult human APOE targeted replacement mice.The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease.ApoE4-specific Misfolded Intermediate Identified by Molecular Dynamics Simulations.Effects of environmental enrichment on spatial memory and neurochemistry in middle-aged mice.Human apolipoprotein E4 targeted replacement in mice reveals increased susceptibility to sleep disruption and intermittent hypoxia.Association of APOE e4 and cerebrovascular pathology in traumatic brain injuryLifelong vitamin E intake retards age-associated decline of spatial learning ability in apoE-deficient mice.Apolipoprotein (apo) E4 and Alzheimer's disease: unique conformational and biophysical properties of apoE4 can modulate neuropathology.Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions.Apolipoprotein E and cholesterol in aging and disease in the brainApolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities.Regulation of IL-1β-induced cyclooxygenase-2 expression by interactions of Aβ peptide, apolipoprotein E and nitric oxide in human neuroglioma.Reactivity of apolipoprotein E4 and amyloid beta peptide: lysosomal stability and neurodegeneration.Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc.Apolipoprotein E4 domain interaction occurs in living neuronal cells as determined by fluorescence resonance energy transfer.Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic miceModulation of astrocytic activation by arundic acid (ONO-2506) mitigates detrimental effects of the apolipoprotein E4 isoform after permanent focal ischemia in apolipoprotein E knock-in mice.The number of cysteine residues per mole in apolipoprotein E affects systematically synchronous neural interactions in women's healthy brains.Defective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative function.Association of refractory complex partial seizures with a polymorphism of ApoE genotype.Augmented delayed infarct expansion and reactive astrocytosis after permanent focal ischemia in apolipoprotein E4 knock-in mice.Transcriptional Effects of ApoE4: Relevance to Alzheimer's Disease.Intraneuronal amyloid-beta plays a role in mediating the synergistic pathological effects of apoE4 and environmental stimulation.Increased vulnerability to focal ischemic brain injury in human apolipoprotein E4 knock-in mice.Apolipoprotein E epsilon4 allele affects the relationship between stress and depression in caregivers of patients with Alzheimer's disease.
P2860
Q21202840-85F11C28-6A0D-4EE7-A018-D42ADB6D9F12Q22248091-1805C143-BA2E-4A2C-8279-3FD33CA1B3CEQ28284354-D7DF9DED-9799-4DC7-BC60-29301A61D456Q28383537-D6F25511-A937-40C2-A0B0-763A2E750706Q28508278-9D01B858-3BA4-4691-BF22-4148D333BBBFQ28570722-60377018-AE63-45FD-B729-6472C6174E83Q30539979-CF59C2A6-8CF0-43A6-A7E2-A59D4A12A77FQ33337322-32D690C0-F9C6-48C8-BFFA-5535E025A99BQ34258228-2FBBE19C-2680-4AEF-8242-88355A156461Q34627558-0F2BA998-FB70-4AB2-9594-C93BA7388AD7Q34976296-ED39C0EB-766A-4CA9-B125-BD27E0097E11Q35024426-352C1CD5-110F-47B2-AEA5-9CF32C1E944DQ35147562-7A45958A-9D0C-464B-A73E-3ED536701AF4Q35444823-9524777F-86C3-4309-B192-96A6A7D4069CQ35823248-81497BBC-DC07-40A2-954D-EE37BE67ED85Q36065414-F1762EDB-F184-4E0D-A65A-E62CC862834DQ36115297-960FED6B-6BAF-4C59-90B9-522422A01053Q36142917-BE36EF26-CF5F-4BBE-A660-4E8FF5B67178Q36272907-412A6D14-2B91-467A-B340-74F69BEF988EQ36546467-0318B843-FFB3-4298-B5D5-C26FEF433490Q36918114-8E5128EC-E6AD-4447-9482-66DCABD3A360Q37009967-72863BAD-A449-4CD4-84B8-91225B35D0F7Q37060457-902E6C75-7A13-4BCF-B0B5-64A92A2233D0Q39439875-DC490F76-053E-4009-B46B-A2DAC7099EF1Q40349274-EEE116D1-13E4-4888-B3C3-89597F5C3913Q40523596-83840B7C-28D2-480F-9F25-310141FA3CCBQ40571686-666467DE-0BC0-4C47-9256-ACF9C5909980Q42045406-E475B9C4-7BB0-4BBC-B578-8C988FE78E95Q45250144-67FFA405-50B2-4BED-B872-DAA130ED601FQ45730801-0F2A200E-2815-4064-92F0-670057B6402CQ46644344-1CB9CCD0-0319-4FFD-9D3E-CA3F1CB0121CQ46733684-3A9C1DFA-A928-4FFA-8ECB-4850E3E03C25Q47385360-174B675A-8CEF-45B7-B18F-0009B83FB153Q47844521-1FA2DB56-AAAA-4CF6-A160-49161DC476CEQ48089465-8B569A88-6704-48CB-88BA-B435C58D953CQ48363901-1A03E028-9A08-4F3A-A4E4-A3AA5BA84C6CQ51963514-5F29B6ED-E9A5-46D2-9985-0D113D5DA49F
P2860
Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Dominant negative effects of a ...... of neurodegenerative disease.
@en
type
label
Dominant negative effects of a ...... of neurodegenerative disease.
@en
prefLabel
Dominant negative effects of a ...... of neurodegenerative disease.
@en
P2093
P1433
P1476
Dominant negative effects of a ...... of neurodegenerative disease.
@en
P2093
Wyss-Coray T
P304
P356
10.1016/S0306-4522(00)00069-5
P407
P577
2000-01-01T00:00:00Z